Cargando…
A window-of-opportunity biomarker study of etodolac in resectable breast cancer
Observational data show that nonsteroidal anti-inflammatory drug (NSAID) use is associated with a lower rate of breast cancer. We evaluated the effect of etodolac, an FDA-approved NSAID reported to inhibit cyclooxygenase (COX) enzymes and the retinoid X receptor alpha (RXR), on rationally identified...
Autores principales: | Schwab, Richard B, Kato, Shumei, Crain, Brian, Pu, Minya, Messer, Karen, Weidner, Noel, Blair, Sarah L, Wallace, Anne M, Carson, Dennis A, Parker, Barbara A |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4618628/ https://www.ncbi.nlm.nih.gov/pubmed/26275572 http://dx.doi.org/10.1002/cam4.512 |
Ejemplares similares
-
Randomized Controlled Trial of Etodolac versus Combination of Etodolac and Eperisone in Patients of Knee Osteoarthritis
por: Kaur, Navjot, et al.
Publicado: (2013) -
R-etodolac is a more potent Wnt signaling inhibitor than enantiomer, S-etodolac
por: Roberts, JoAnn S., et al.
Publicado: (2022) -
Mutational Profiling Can Establish Clonal or Independent Origin in Synchronous Bilateral Breast and Other Tumors
por: Bao, Lei, et al.
Publicado: (2015) -
Etodolac and the risk of acute pancreatitis
por: Liao, Kuan-Fu, et al.
Publicado: (2017) -
Spectrophotometric determination of etodolac in pure form and pharmaceutical formulations
por: Gouda, Ayman A, et al.
Publicado: (2008)